Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S. Int J Nanomedicine. 2019;14:5679–5690.The authors of this paper have advised that by their mistake, they omitted an important note from the Acknowledgments section on page 5688.Read the original article
Guardado en:
Autores principales: | Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/089b3c9254d64f899ca5adba19a3ed48 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted delivery of doxorubicin to HER2 positive tumor models
por: Gomari H, et al.
Publicado: (2019) -
Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies
por: Noori Koopaei M, et al.
Publicado: (2011) -
Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
por: Yousefpour P, et al.
Publicado: (2011) -
Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery
por: Joo JY, et al.
Publicado: (2015) -
Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes
por: Shi M, et al.
Publicado: (2018)